RAPID Response, Notified Body Needs, CDRH Retirement, and More

article image
ARTICLE SUMMARY:

Medtech groups formally respond to CMS’ RAPID proposal for regulatory-reimbursement alignment; notified bodies renew their push to influence MDR reform plans; CDRH research director retires; IMDRF addresses e-labeling; and updates from India, Taiwan, and Canada.

RAPID Response

CMS heard from more than 100 device firms, innovators, and other stakeholders in recent days about its plan for a Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. Written feedback was due October 13 for the August 11 proposal, and many are pressing the agency to expand the scope of program. The RAPID pathway would task FDA and CMS to engage with manufacturers prior to the company’s investigational device exemption (IDE) trial, initiating a process promising FDA authorization and a national Medicare coverage proposal on the same day.

Multiple individual companies currently conducting pivotal trials for Breakthrough Devices weighed in, urging CMS to add a transitional path allowing devices like theirs to participate in RAPID even if they have already launched a pivotal study. CSA Medical, for instance, argued in October 7 comments that the fact it has already launched a pivotal trial for the firm’s RejuvenAir Metered CryoSpray for chronic obstructive pulmonary disease “should not, by itself, preclude CMS from evaluating whether the existing evidence is sufficient to support Medicare coverage or identifying any remaining evidence needs that could be addressed in a practical and least burdensome manner.”

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: